Quantum Innovations Revolutionizes Cardiac Surgery Monitoring
June 21, 2024, 9:32 am
Quantum Innovations
Total raised: $10.81M
Quantum Innovations, a Polish medtech company, has secured nearly €10 million in funding for their groundbreaking sensor technology designed to revolutionize cardiac surgery monitoring. Led by Grzegorz Suwalski, M.D, PhD, the team has developed the world's first sensor technology for monitoring organs during surgery and transplantation. Their innovative solutions, Heart Sense and Heart Guard, provide real-time ECG monitoring and tissue metabolism tracking, respectively, during cardiac procedures.
The funding, led by Vinci IQ ASI and supported by MedTech Holding, will be used to establish a production line, conduct regulatory and clinical trials, and enter global markets. With cardiovascular diseases remaining a leading cause of mortality worldwide, the need for advanced medical technologies like those developed by Quantum Innovations is more critical than ever.
The technology developed by Quantum Innovations aims to address the lack of precision and continuous monitoring in current surgical tools and equipment. By providing surgeons with real-time data and insights, their solutions have the potential to significantly reduce complications and mortality rates associated with cardiac surgeries.
Grzegorz Suwalski, Founder and CEO of Quantum Innovations, emphasized the importance of their technology in improving medical procedures and patient outcomes. The ability to examine the ECG of the heart in various positions and monitor tissue metabolism can help cardiac teams overcome knowledge gaps and prevent dangerous complications during surgeries.
The investment in Quantum Innovations reflects the growing importance of medical technologies in advancing healthcare and reducing the burden of cardiovascular diseases. With the support of Vinci IQ ASI and MedTech Holding, Quantum Innovations is poised to make a significant impact in the field of cardiac surgery monitoring.
As the company moves forward with production and clinical trials, the potential for their technology to become a standard in cardiothoracic surgeries is promising. By leveraging cutting-edge sensor technology, Quantum Innovations is paving the way for safer and more successful cardiac procedures, ultimately saving lives and improving patient outcomes.
The funding, led by Vinci IQ ASI and supported by MedTech Holding, will be used to establish a production line, conduct regulatory and clinical trials, and enter global markets. With cardiovascular diseases remaining a leading cause of mortality worldwide, the need for advanced medical technologies like those developed by Quantum Innovations is more critical than ever.
The technology developed by Quantum Innovations aims to address the lack of precision and continuous monitoring in current surgical tools and equipment. By providing surgeons with real-time data and insights, their solutions have the potential to significantly reduce complications and mortality rates associated with cardiac surgeries.
Grzegorz Suwalski, Founder and CEO of Quantum Innovations, emphasized the importance of their technology in improving medical procedures and patient outcomes. The ability to examine the ECG of the heart in various positions and monitor tissue metabolism can help cardiac teams overcome knowledge gaps and prevent dangerous complications during surgeries.
The investment in Quantum Innovations reflects the growing importance of medical technologies in advancing healthcare and reducing the burden of cardiovascular diseases. With the support of Vinci IQ ASI and MedTech Holding, Quantum Innovations is poised to make a significant impact in the field of cardiac surgery monitoring.
As the company moves forward with production and clinical trials, the potential for their technology to become a standard in cardiothoracic surgeries is promising. By leveraging cutting-edge sensor technology, Quantum Innovations is paving the way for safer and more successful cardiac procedures, ultimately saving lives and improving patient outcomes.